Alembic Pharma Q4 profit up 29% as US formulations business grows 11%; declares ₹12 dividend
Published on: May 15, 2026, 3:47 p.m. | Source: CNBC TV18
Alembic Pharmaceuticals reported a 29% year-on-year rise in Q4 consolidated net profit to ₹202 crore, aided by 11% growth in the US formulations business and steady India branded sales. Revenue rose 4.4% to ₹1,848 crore, while EBITDA margin narrowed to 12.3%. The company also entered the US branded pharmaceuticals market with the launch of Pivya and recommended a dividend of ₹12 per share.
